Skip to main content

Table 4 Adjusted hazard ratios for darunavir/ritonavir vs. atazanavir/ritonavir from sensitivity analyses

From: Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients

Analysis Virologic Failure or Other Discontinuation Virologic Failure Discontinuations due to Virologic Failure Other Discontinuation Virologic Suppression
aHR (95% CI) p aHR (95% CI) p aHR (95% CI) p aHR (95% CI) p aHR (95% CI) p
0 Original Model 0.76 (0.56,1.03) 0.08 0.50 (0.28,0.91) 0.02 0.00 (0.00,0.00) <.0001 0.93 (0.65,1.33) 0.68 0.99 (0.82,1.21) 0.96
1 Subgroup by Province
  ON/QC Only 0.73 (0.51,1.06) 0.10 0.90 (0.44,1.86) 0.78 0.00 (0.00,0.00) <.0001 0.72 (0.47,1.11) 0.14 0.99 (0.78,1.27) 0.96
  BC Only 0.69 (0.34,1.42) 0.32 0.41 (0.09,1.78) 0.23 0.00 (0.00,0.00) <.0001 0.93 (0.43,2.04) 0.86 0.78 (0.46,1.32) 0.35
2 Subgroup by Baseline VL
  < 100,000 copies/mL 0.66 (0.42,1.03) 0.07 0.47 (0.18,1.19) 0.11 0.00 (0.00,0.00) <.0001 0.82 (0.49,1.36) 0.44 0.97 (0.76,1.23) 0.78
  ≥ 100,000 copies/mL 0.86 (0.56,1.33) 0.49 0.54 (0.25,1.16) 0.11 0.00 (0.00,0.00) <.0001 1.16 (0.68,2.00) 0.58 1.11 (0.81,1.53) 0.51
3 2010–2012 Only 0.81 (0.56,1.18) 0.27 0.55 (0.26,1.14) 0.11 0.00 (0.00,0.00) <.0001 0.96 (0.63,1.48) 0.87 0.98 (0.76,1.26) 0.87
4 Simplification discontinuations included as competing risks 0.75 (0.54,1.03) 0.07 0.50 (0.28,0.91) 0.02 0.00 (0.00,0.00) <.0001 0.92 (0.63,1.34) 0.65 0.99 (0.82,1.21) 0.96
5 SMC-FCS Imputation 0.76 (0.56, 1.04) 0.08 0.5 (0.28, 0.9) 0.02 0.00 (0.00,0.00) <.0001 0.91 (0.62, 1.34) 0.64 0.98 (0.8, 1.2) 0.84
  1. aHR adjusted hazard ratio, VL viral load